We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Linda
Sharp
+44 (0)1912086275
SWEET@warwick.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Breast cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
In 2016, 11,563 women died from breast cancer in the UK. Most would have been prescribed hormone therapy (HT); sometimes known as endocrine therapy, which blocks the effect of oestrogen on breast cancer cells. HT is prescribed as a daily tablet, usually for at least 5 years and often up to 10 years. When women stop taking HT prematurely, or don’t take it as prescribed (known as “poor adherence”), they have up to a three times higher chance of the cancer returning and dying from cancer. At least 20% of women have poor adherence after 2 years and around 50% by 5 years. Previous research has identified reasons for poor adherence, including feeling negative or concerned about HT; not fully understanding its importance; side-effects; feeling unsupported; and forgetfulness. SWEET is an NIHR-funded research programme which, supported by a Patient Advisory Group and Clinical Reference Group, will develop and test a support package to support women taking treatment as recommended. The aim of this study is to determine the clinical effectiveness of the trial intervention in reducing poor adherence to treatment and improving quality of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Male2. Evidence of metastatic disease i.e. stage 4 disease (M1 regardless of T and N status)3. Have cognitive impairment sufficient to preclude participation, as judged by the clinical team4. Had previous AET (for another breast cancer)5. Are unable to read and understand English
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Linda
Sharp
+44 (0)1912086275
SWEET@warwick.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust and funded by NIHR Central Commissioning Facility (CCF); Grant Codes: NIHR200098.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 57385
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
